📄 medicine

A MBene-based electrochemical aptasensor for label-free detection of EpCAM-overexpressing cancer cells

This study presents a label-free electrochemical aptasensor utilizing MBene nanosheets for the highly sensitive and specific detection of EpCAM-overexpressing cancer cells, demonstrating clinical viability through successful discrimination of malignant and benign endometrial samples.

Original authors: Min Li, Yue Jiang, Yang Huang, Wei Chen, Yan Li, Dongxin Liang, Yuqi Wang, Qian Qie, Jiaxian Yuan, Jiahui Zhang, Yuan Zhang, Siyu Yang, Xin He, Zhaoyi Zhang, Liping Du, Chunsheng Wu, Qiling Li

Published 2026-07-08

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Min Li, Yue Jiang, Yang Huang, Wei Chen, Yan Li, Dongxin Liang, Yuqi Wang, Qian Qie, Jiaxian Yuan, Jiahui Zhang, Yuan Zhang, Siyu Yang, Xin He, Zhaoyi Zhang, Liping Du, Chunsheng Wu, Qiling Li

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Idea: A "Molecular Magnet" for Cancer Cells

Imagine you are trying to find a specific type of needle in a massive haystack. In the world of cancer diagnostics, that "needle" is a specific protein called EpCAM, which is found in huge numbers on the surface of many dangerous cancer cells.

Currently, finding these cells is like using a complicated, expensive machine that requires a team of experts to label the needles with glowing paint before you can see them. It's slow, costly, and hard to do right at a doctor's office.

This paper introduces a new, simpler tool: a label-free electrochemical aptasensor. Think of this as a high-tech "smart trap" that can find those cancer cells instantly without needing any glowing paint or complex machinery.

The Secret Ingredient: MBene

The heart of this new sensor is a material called MBene.

The Analogy: Imagine a standard piece of paper (a normal electrode). Now, imagine crumpling that paper into a tiny, rough ball and then stretching it out into a super-thin, porous sponge. That sponge is MBene.
Why it matters: Because it is so rough and porous, it has a massive surface area. It acts like a super-conductive highway for electricity. This allows the sensor to "feel" changes very quickly and clearly.

How the Sensor Works: The "Velcro" Trap

The researchers built a three-layer trap on a tiny gold chip (like a credit card-sized sensor):

The Base Layer (MBene): They glued the MBene "sponge" onto the gold chip. This makes the surface conductive and ready to catch things.
The Trap (Aptamers): They attached special DNA strands called aptamers to the sponge.
- The Metaphor: Think of these aptamers as Velcro strips designed to stick only to the EpCAM protein. They ignore everything else.
The Lock (MCH): They filled in the empty spaces with a "blocking agent" (MCH) so that nothing sticky could get stuck where it shouldn't.

The Detection Process:
When a sample (like a drop of fluid from a patient) is placed on this sensor:

If cancer cells are present, their EpCAM proteins grab onto the Velcro aptamers.
This creates a physical "traffic jam" on the surface.
The sensor measures electricity flowing across the surface. When the cancer cells stick, they block the electricity, causing a measurable change in resistance.
No labels needed: Because the cells themselves block the electricity, you don't need to dye them or tag them. The cells are the signal.

What They Found (The Results)

The team tested this "smart trap" in several ways:

Super Sensitive: It could detect the EpCAM protein at incredibly low levels (as low as 8.86 femtograms per milliliter). That's like finding a single grain of sand in a swimming pool.
Cell Counting: It could count cancer cells directly, detecting as few as 7 cells in a milliliter of fluid.
Specificity: It was very picky. When they tested it against healthy cells (which don't have the EpCAM protein), the sensor barely reacted. It only "screamed" when it caught the cancer cells.
Real-World Test: They didn't just test it in a lab with fake samples. They tested it on 44 real clinical samples from patients with endometrial (uterine) issues.
- The sensor successfully distinguished between malignant (cancerous) and benign (non-cancerous) cases.
- Using a computer algorithm, they achieved an accuracy rate of about 86%, which is comparable to or better than some current standard tests.

Why This Matters

The paper claims this is a breakthrough because:

It's Label-Free: No need for expensive dyes or complex chemical labeling steps.
It's Fast and Simple: It uses a simple electrical measurement instead of a microscope or a large lab machine.
It's Portable: Because it uses a small screen-printed gold chip, this technology could eventually be made into a handheld device for doctors to use right in their offices (Point-of-Care).

The Bottom Line

The researchers successfully built a tiny, electrical "Velcro trap" using a special material called MBene. This trap can sniff out cancer cells by their unique protein signature without needing any fancy labels. In tests with real patient samples, it worked well enough to tell the difference between cancer and non-cancer cases, offering a promising new way to make cancer detection faster, cheaper, and easier.

Technical Summary: MBene-Based Electrochemical Aptasensor for Label-Free Detection of EpCAM-Overexpressing Cancer Cells

Problem Statement
Accurate detection of tumor cells is critical for cancer diagnostics and early intervention. Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein extensively overexpressed in epithelial-derived malignancies, serving as a key biomarker. However, conventional detection methods such as immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and flow cytometry rely on labeling, involve labor-intensive multi-step processing, and require specialized equipment. These limitations restrict their utility in point-of-care (POC) settings. While electrochemical biosensors offer advantages in sensitivity, speed, and portability, many existing systems depend on complex surface modifications or intricate signal amplification mechanisms that compromise practicality and reproducibility. There is a need for a label-free, accessible strategy that balances operational simplicity with high analytical performance for detecting EpCAM-overexpressing cancer cells.

Methodology
The study presents a label-free electrochemical aptasensor constructed on screen-printed gold electrodes (SPGEs) using two-dimensional MBene nanosheets as a functional interface.

Material Synthesis: Two-dimensional CrB MBene nanosheets were synthesized via the selective etching of a Cr₂AlB₂ precursor using 2 M HCl. This process removed the interleaved aluminum layers, resulting in a porous, layered morphology with high surface roughness and oxygen-containing surface terminations (–OH, B–O).
Sensor Fabrication: The sensing interface was assembled stepwise on SPGEs:
1. MBene Modification: MBene nanosheets were drop-cast onto the gold working electrode to create a conductive, biocompatible interface.
2. Aptamer Immobilization: Thiolated EpCAM-specific aptamers were immobilized onto the MBene surface via Au–S bonds.
3. Blocking: Non-specific binding sites were blocked with 6-mercapto-1-hexanol (MCH).
Detection Principle: The sensor operates via Electrochemical Impedance Spectroscopy (EIS). The binding of EpCAM proteins or EpCAM-overexpressing cells to the aptamers creates an insulating layer that impedes electron transfer, resulting in an increase in charge transfer resistance ( $R_{ct}$ ). This change ( $\Delta R_{ct}$ ) serves as the quantitative signal.
Validation Models: The system was validated using:
- Cell Lines: Ishikawa cells (EpCAM-overexpressing) and HEK293T cells (EpCAM-negative control).
- Clinical Samples: 44 real clinical endometrial cytological samples (22 malignant, 22 benign) collected via Li-Brush.
Data Analysis: Diagnostic performance on clinical samples was evaluated using machine learning models (k-nearest neighbors, decision tree, SVM, logistic regression), with logistic regression identified as the optimal classifier.

Key Contributions

Novel Material Application: This work introduces MBene, a boride-based analogue of MXene, as a sensing matrix for electrochemical aptasensing. The study demonstrates that MBene's high conductivity, large active surface area, and abundant surface sites facilitate efficient electron transfer and stable aptamer immobilization.
Label-Free Architecture: The platform achieves sensitive detection without the need for enzymatic labels or complex signal amplification, relying instead on the intrinsic impedance changes caused by target binding.
Clinical Translation: Moving beyond spiked laboratory samples, the study validates the sensor using real patient-derived endometrial cytological samples, providing translational evidence for its applicability in complex biological matrices.

Results

Characterization: SEM, XRD, XPS, and FTIR confirmed the successful transformation of Cr₂AlB₂ into 2D CrB MBene with a porous structure and surface hydroxyl groups.
Analytical Performance:
- Protein Detection: The sensor exhibited a linear response to EpCAM protein from 10 fg mL⁻¹ to 100 pg mL⁻¹, with a limit of detection (LOD) of 8.86 fg mL⁻¹.
- Cell Detection: A linear response was observed for EpCAM-overexpressing Ishikawa cells from 10¹ to 10⁵ cells mL⁻¹, achieving an LOD of 7 cells mL⁻¹.
Specificity and Stability: The sensor showed high specificity, distinguishing Ishikawa cells from HEK293T cells with minimal interference from non-target cells. It demonstrated excellent reproducibility (RSD < 5%) and storage stability, retaining ~92% of its initial signal after 14 days at 4°C.
Clinical Performance: In the analysis of 44 endometrial cytological samples, the sensor effectively discriminated between malignant and benign cases. The logistic regression model achieved a sensitivity of 86.36%, specificity of 86.36%, and an Area Under the Curve (AUC) of 0.897. This performance was comparable to or balanced against conventional modalities like transvaginal ultrasound and serum biomarkers, while avoiding the invasiveness of tissue biopsy.

Significance
The paper claims that this work establishes a feasible electrochemical sensing approach for the label-free detection of EpCAM-overexpressing cancer cells. By leveraging the conductive and functional properties of MBene nanosheets, the platform offers a strategy that is sensitive, specific, and reproducible. The successful validation with clinical cytological samples suggests potential applicability in clinical analysis and point-of-care diagnostics. The authors position this work as a complementary strategy to existing diagnostic tools, highlighting the expanded application of MBene nanomaterials in biosensing. The study acknowledges limitations, such as the relatively small cohort size, and calls for future multi-center validation to further optimize clinical sensitivity and robustness.